CardioDynamics International --CDIC-- Announces Significant 100+ Patient BioZ Study Results at Society of Academic Emergency Medicine Annual Meeting, San Francisco.

Business Editors/High Tech Writers

SAN DIEGO--(BW HealthWire)--May 30, 2000

Company's Proprietary Technology Improves

Emergency Department Treatment

CardioDynamics International Corporation (Nasdaq:CDIC), manufacturer of BioZ(R) noninvasive digital cardiac function monitoring systems, today announced the results of a significant 100+ patient clinical study presented at the Society of Academic Emergency Medicine 2000 Annual Meeting held May 22-25, 2000 in San Francisco, California.

The study, presented by David A. Guss, M.D., Director of Department of Emergency Department, University of California San Diego Medical Center, demonstrated the Company's BioZ Impedance Cardiography (ICG) technology's ability to improve diagnostic and therapeutic decision making during evaluation of critically ill patients in the emergency department.

In this study, treating physicians estimated cardiac output, stroke volume and systemic vascular resistance and then made initial diagnosis and therapy. The same parameters were then objectively obtained utilizing the BioZ.com. Based upon discordance between physician estimates and the BioZ.com's parameters, study investigators identified that 14% of the patients potentially received incorrect therapy based upon estimates. The study concluded that the BioZ ICG technology offers a means to noninvasively measure objective vital parameters, which are of clinical significance in the treatment of emergency patients.

Each year, more than 5 million people with chest pain are admitted to emergency departments. Of those patients, 1.5 million suffer a heart attack or have angina, a condition in which the heart muscle does not get an adequate supply of blood or oxygen. An estimated 2-13% of heart attacks each year are misdiagnosed, and the patients are inappropriately sent home from the emergency department, resulting in greater than 25% mortality rate. On average, 16-17% of emergency department patients will ultimately be admitted to the hospital.

"The results of this recent study further demonstrates the need for noninvasive, cost-effective methods of obtaining vital hemodynamic data in yet another treatment area of healthcare. Time is critical in the emergency department, and the ability to rapidly diagnose and provide the proper therapy is of utmost importance," stated Michael K. Perry, Chief Executive Officer of CardioDynamics. "In the emergency department, our technology empowers physicians with the data they need to quickly assess, diagnose and treat patients, improving patient outcomes and reducing costly hospitalization admittance and stay. There are approximately 7,800 emergency departments worldwide. Based on an estimate of each department utilizing two BioZ Systems, our potential emergency medicine market is estimated to be over $300 million."

The Society for Academic Emergency Medicine (SAEM) is committed to improving patient care by advancing research and education in emergency medicine. SAEM's vision is to promote ready access to quality emergency care for all patients, to advance emergency medicine as an academic and clinical discipline, and to maintain the highest professional standards as clinicians, teachers, and researchers. To address the growing national concerns about patient safety and medical error, the Society is currently requesting papers that specifically address errors in Emergency Medicine.

CardioDynamics, with headquarters in San Diego, is a medical technology and information solutions company committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The Company's primary products, the BioZ(R) System and BioZ.com(R), utilize proprietary BioZ Impedance Cardiography (ICG) technology to noninvasively provide medical professionals with hemodynamic data not previously available in the physicians office and many hospital settings. Just as Electrocardiography (ECG) measures the heart's electrical characteristics, ICG makes it possible to noninvasively measure the heart's mechanical (blood flow) characteristics. Physicians around the world are currently using the BioZ products, including major medical centers such as the Mayo Clinic (Rochester), Stanford University School of Medicine, (Palo Alto), University of California San Francisco (San Francisco), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $5 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(R) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1999 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.